Metabolic syndrome and mitochondrial dysfunction: insights from preclinical studies with a mitochondrially targeted antioxidant
- PMID: 22226828
- PMCID: PMC3992111
- DOI: 10.1016/j.freeradbiomed.2011.12.014
Metabolic syndrome and mitochondrial dysfunction: insights from preclinical studies with a mitochondrially targeted antioxidant
Figures
Comment on
-
The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+/-/ApoE-/- mice.Free Radic Biol Med. 2012 Mar 1;52(5):841-9. doi: 10.1016/j.freeradbiomed.2011.11.026. Epub 2011 Dec 14. Free Radic Biol Med. 2012. PMID: 22210379
References
-
- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359. - PubMed
-
- Boudreau DM, Malone DC, Raebel MA, Fishman PA, Nichols GA, Feldstein AC, Boscoe AN, Ben-Joseph RH, Magid DJ, Okamoto LJ. Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord. 2009;7:305–314. - PubMed
-
- Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689. - PubMed
-
- Reaven G. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
